Neodymium:YAG laser coagulation prostatectomy: 3 years of experience with 227 patients.

PURPOSE For 3 years we prospectively followed a cumulative cohort of men who underwent neodymium:YAG laser coagulation prostatectomy to relieve bladder outlet obstruction to determine the safety, efficacy and durability of this procedure. MATERIALS AND METHODS A total of 227 men with symptomatic bladder outlet obstruction was treated with the Urolase side-firing laser fiber between October 15, 1991 and October 15, 1994. Voiding outcomes, including peak urinary flow rates, residual urine volumes and American Urological Association symptom scores, were measured with time, and immediate and long-term complications were assessed. RESULTS Median patient followup was 26 months (maximum 42). Significant improvement occurred in all measured voiding parameters, including 133% in peak flow rates and 61% in symptom scores 1 year postoperatively. Overall 87% of patients noticed improved quality of life as a result of surgery. Minimum postoperative followup was 6 months in all cases. Complications included prostatitis in 2.6% of patients, urethral stricture in 1.8%, bladder neck contracture in 4.4% and reoperation for residual prostate tissue in 5.3%. CONCLUSIONS Neodymium:YAG laser coagulation of the prostate represents an efficacious surgical intervention for symptomatic bladder outlet obstruction with minimal associated morbidity. Voiding outcomes are durable through 3 years.

[1]  J. Kabalin,et al.  Urolase laser prostatectomy in patients on warfarin anticoagulation: a safe treatment alternative for bladder outlet obstruction. , 1993, Urology.

[2]  J. Kabalin.  Stage A prostate cancer today. , 1993, The Journal of urology.

[3]  J. Kabalin,et al.  Dosimetry studies utilizing the urolase right angle firing neodymium: YAG laser fiber , 1994, Lasers in surgery and medicine.

[4]  A. Costello,et al.  Management of benign prostatic hyperplasia by transurethral laser ablation in patients treated with warfarin anticoagulation. , 1994, The Journal of urology.

[5]  R. Dmochowski,et al.  Outpatient visual laser-assisted prostatectomy under local anesthesia. , 1994, Urology.

[6]  H. Krakauer,et al.  Mortality and reoperation following prostatectomy: outcomes in a Medicare population. , 1991, Urology.

[7]  A. Costello,et al.  Laser ablation of the prostate in patients with benign prostatic hypertrophy. , 1992, British journal of urology.

[8]  J. Kabalin.  Laser prostatectomy performed with a right angle firing neodymium:YAG laser fiber at 40 watts power setting. , 1995, The Journal of urology.

[9]  M. Terris,et al.  Dosimetry studies utilizing the urolase right‐angle firing Neodymium: YAG laser fiber in the human prostate , 1996, Lasers in surgery and medicine.

[10]  R. Bruskewitz,et al.  3-year followup of urinary symptoms after transurethral resection of the prostate. , 1986, The Journal of urology.

[11]  J. Nordling,et al.  Long term results of transurethral and transvesical prostatectomy. A randomized study. , 1986, Scandinavian journal of urology and nephrology.

[12]  J. Kabalin,et al.  Comparative study of laser versus electrocautery prostatic resection: 18-month followup with complex urodynamic assessment. , 1995, Journal of Urology.

[13]  J. Kabalin,et al.  Costs of minimally invasive laser surgery compared with transurethral electrocautery resection of the prostate. , 1995, The Western journal of medicine.

[14]  David M. Eddy,et al.  Benign Prostatic Hyperplasia: Diagnosis and Treatment , 1998 .

[15]  J P Norris,et al.  Visual laser ablation of the prostate: clinical experience in 108 patients. , 1993, The Journal of urology.

[16]  B Stein,et al.  A prospective randomized comparison of transurethral resection to visual laser ablation of the prostate for the treatment of benign prostatic hyperplasia. , 1995, Urology.